Matches in SemOpenAlex for { <https://semopenalex.org/work/W2264815585> ?p ?o ?g. }
- W2264815585 endingPage "356" @default.
- W2264815585 startingPage "345" @default.
- W2264815585 abstract "In metastatic breast cancer, nab-paclitaxel has been shown to significantly increase progression-free survival compared with solvent-based paclitaxel. The GeparSepto (GBG 69) trial assessed whether weekly nab-paclitaxel could increase the proportion of patients achieving pathological complete response compared with weekly solvent-based paclitaxel, both followed by epirubicin plus cyclophosphamide as neoadjuvant treatment.In a phase 3 randomised trial, we enrolled patients with previously untreated unilateral or bilateral primary invasive breast cancer and randomly assigned them in a 1:1 ratio using dynamic allocation and Pocock minimisation by breast cancer subtype, Ki67 and SPARC expression. Patients were treated for 12 weeks with either intravenous nab-paclitaxel 150 mg/m(2) (after study amendment, 125 mg/m(2)) on days 1, 8, and 15 for four 3-week cycles, or solvent-based intravenous paclitaxel 80 mg/m(2) on days 1, 8, and 15 for four 3-week cycles. Taxane treatment was followed in both groups by intravenous epirubicin 90 mg/m(2) plus intravenous cyclophosphamide 600 mg/m(2) on day 1 for four 3-week cycles. Patients with HER2-positive tumours received concurrent trastuzumab 6 mg/kg (loading dose 8 mg/kg) and pertuzumab 420 mg (loading dose 840 mg) on day 1 of every 3-week cycle. Trastuzumab and pertuzumab were given every 3 weeks concomitantly with chemotherapy for all cycles. This report is the final analysis of the primary endpoint, pathological complete response (ypT0 ypN0), analysed for all patients who started treatment (modified intention to treat). We used a closed test procedure to test for non-inferiority, with the nab-paclitaxel group calculated as non-inferior to the solvent-based paclitaxel group if the lower 95% CI for the OR was above 0·858 (OR equivalent to pathological complete response [33%] minus a 10% non-inferiority margin [3·3%]; 29·7%). We planned to test for superiority only in case of a positive non-inferiority test, using an α of 0·05. Safety was assessed in all patients who received study drug. The trial is registered with ClinicalTrials.gov, number NCT01583426.Between July 30, 2012, and Dec 23, 2013, we randomly assigned 1229 women, of whom 1206 started treatment (606 with nab-paclitaxel and 600 with solvent-based paclitaxel). The nab-paclitaxel dose was reduced after enrolment of 464 participants to 125 mg/m(2) due to increased treatment discontinuation and sensory neuropathy in this group. Pathological complete response occurred more frequently in the nab-paclitaxel group (233 [38%, 95% CI 35-42] patients) than in the solvent-based paclitaxel group (174 [29%, 25-33] patients; OR 1·53, 95% CI 1·20-1·95; unadjusted p=0·00065). The incidence of grade 3-4 anaemia (13 [2%] of 605 patients in the nab-paclitaxel group vs four [1%] of patients in the solvent-based paclitaxel group; p=0·048) and peripheral sensory neuropathy grade 3-4 (63 [10%] patients receiving any nab-paclitaxel dose; 31 [8%] of patients starting with 125 mg/m(2) and 32 [15%] of patients starting with 150 mg/m(2); vs 16 [3%] in the solvent-based paclitaxel group, p<0·001) was significantly higher for nab-paclitaxel than for solvent-based paclitaxel. Overall, 283 (23%) patients were noted to have at least one serious adverse event (based on study drug received), 156 (26%) in the nab-paclitaxel group and 127 (21%) in the solvent-based paclitaxel group (p=0·057). There were three deaths (during epirubicin plus cyclophosphamide treatment) in the nab-paclitaxel group (due to sepsis, diarrhoea, and accident unrelated to the trial) versus one in the solvent-based paclitaxel group (during paclitaxel treatment; cardiac failure).Substituting solvent-based paclitaxel with nab-paclitaxel significantly increases the proportion of patients achieving a pathological complete response rate after anthracycline-based chemotherapy. These results might lead to an exchange of the preferred taxane, solvent-based paclitaxel, for nab-paclitaxel in therapy for primary breast cancer.Celgene, Roche." @default.
- W2264815585 created "2016-06-24" @default.
- W2264815585 creator A5002071285 @default.
- W2264815585 creator A5003405177 @default.
- W2264815585 creator A5004942036 @default.
- W2264815585 creator A5007997038 @default.
- W2264815585 creator A5010482169 @default.
- W2264815585 creator A5011410319 @default.
- W2264815585 creator A5014934109 @default.
- W2264815585 creator A5016987068 @default.
- W2264815585 creator A5024469109 @default.
- W2264815585 creator A5024741688 @default.
- W2264815585 creator A5026613913 @default.
- W2264815585 creator A5033698551 @default.
- W2264815585 creator A5040331693 @default.
- W2264815585 creator A5046991493 @default.
- W2264815585 creator A5049792647 @default.
- W2264815585 creator A5052454978 @default.
- W2264815585 creator A5056688392 @default.
- W2264815585 creator A5056873538 @default.
- W2264815585 creator A5057181684 @default.
- W2264815585 creator A5069170386 @default.
- W2264815585 creator A5071658752 @default.
- W2264815585 creator A5074391693 @default.
- W2264815585 creator A5087224341 @default.
- W2264815585 creator A5087559224 @default.
- W2264815585 creator A5089392438 @default.
- W2264815585 date "2016-03-01" @default.
- W2264815585 modified "2023-10-13" @default.
- W2264815585 title "Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto—GBG 69): a randomised, phase 3 trial" @default.
- W2264815585 cites W1954890750 @default.
- W2264815585 cites W1977737254 @default.
- W2264815585 cites W1991525295 @default.
- W2264815585 cites W2000366267 @default.
- W2264815585 cites W2026718377 @default.
- W2264815585 cites W2029419388 @default.
- W2264815585 cites W2043506695 @default.
- W2264815585 cites W2044133019 @default.
- W2264815585 cites W2048059530 @default.
- W2264815585 cites W2073716382 @default.
- W2264815585 cites W2075894019 @default.
- W2264815585 cites W2084370697 @default.
- W2264815585 cites W2086064725 @default.
- W2264815585 cites W2089265205 @default.
- W2264815585 cites W2095861620 @default.
- W2264815585 cites W2095865154 @default.
- W2264815585 cites W2096745115 @default.
- W2264815585 cites W2098333537 @default.
- W2264815585 cites W2114886164 @default.
- W2264815585 cites W2117239059 @default.
- W2264815585 cites W2117972559 @default.
- W2264815585 cites W2117984780 @default.
- W2264815585 cites W2123528875 @default.
- W2264815585 cites W2123591186 @default.
- W2264815585 cites W2127395702 @default.
- W2264815585 cites W2131065012 @default.
- W2264815585 cites W2137228442 @default.
- W2264815585 cites W2147415463 @default.
- W2264815585 cites W2151262170 @default.
- W2264815585 cites W2153017356 @default.
- W2264815585 cites W2155808778 @default.
- W2264815585 cites W802625524 @default.
- W2264815585 doi "https://doi.org/10.1016/s1470-2045(15)00542-2" @default.
- W2264815585 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26869049" @default.
- W2264815585 hasPublicationYear "2016" @default.
- W2264815585 type Work @default.
- W2264815585 sameAs 2264815585 @default.
- W2264815585 citedByCount "286" @default.
- W2264815585 countsByYear W22648155852015 @default.
- W2264815585 countsByYear W22648155852016 @default.
- W2264815585 countsByYear W22648155852017 @default.
- W2264815585 countsByYear W22648155852018 @default.
- W2264815585 countsByYear W22648155852019 @default.
- W2264815585 countsByYear W22648155852020 @default.
- W2264815585 countsByYear W22648155852021 @default.
- W2264815585 countsByYear W22648155852022 @default.
- W2264815585 countsByYear W22648155852023 @default.
- W2264815585 crossrefType "journal-article" @default.
- W2264815585 hasAuthorship W2264815585A5002071285 @default.
- W2264815585 hasAuthorship W2264815585A5003405177 @default.
- W2264815585 hasAuthorship W2264815585A5004942036 @default.
- W2264815585 hasAuthorship W2264815585A5007997038 @default.
- W2264815585 hasAuthorship W2264815585A5010482169 @default.
- W2264815585 hasAuthorship W2264815585A5011410319 @default.
- W2264815585 hasAuthorship W2264815585A5014934109 @default.
- W2264815585 hasAuthorship W2264815585A5016987068 @default.
- W2264815585 hasAuthorship W2264815585A5024469109 @default.
- W2264815585 hasAuthorship W2264815585A5024741688 @default.
- W2264815585 hasAuthorship W2264815585A5026613913 @default.
- W2264815585 hasAuthorship W2264815585A5033698551 @default.
- W2264815585 hasAuthorship W2264815585A5040331693 @default.
- W2264815585 hasAuthorship W2264815585A5046991493 @default.
- W2264815585 hasAuthorship W2264815585A5049792647 @default.
- W2264815585 hasAuthorship W2264815585A5052454978 @default.
- W2264815585 hasAuthorship W2264815585A5056688392 @default.
- W2264815585 hasAuthorship W2264815585A5056873538 @default.
- W2264815585 hasAuthorship W2264815585A5057181684 @default.
- W2264815585 hasAuthorship W2264815585A5069170386 @default.